Article: Antihistamine may arrest cognitive decline in AD.(Neurology)(Alzheimer's disease)(Clinical report)

CHICAGO -- An off-the-market antihistamine, previously shown to slow cognitive decline over 1 year in Alzheimer's patients, continued to preserve cognition and memory during a 6-month open-label extension trial.

The drug, dimebon, also stabilized cognition in patients who started on it after taking placebo during the original trial, Dr. Jeffrey Cummings said at the International Conference on Alzheimer's Disease.

"People initially treated with placebo and then crossed over to dimebon did not show the same level of benefit as those people who took dimebon for 18 months after starting the [initial] study," said Dr. Cummings, the Augustus S. Rose Professor of Neurology ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!